CRTHF (CARsgen Therapeutics Holdings) Research & Development: $34.48 Mil (TTM As of Dec. 2025)


CRTHF CARsgen Therapeutics Holdings Ltd CRTHF
24 GF Score
Price $2.09
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings Research & Development?

CARsgen Therapeutics Holdings CRTHF +0.67% 24 Research & Development is $34.48 Mil as of Dec. 2025. GuruFocus rates CRTHF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CARsgen Therapeutics Holdings's Research & Development for the six months ended in Dec. 2025 was $16.35 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $34.48 Mil.

CARsgen Therapeutics Holdings  (OTCPK:CRTHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CARsgen Therapeutics Holdings Research & Development Related Terms

CARsgen Therapeutics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings Research & Development Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 78.77 97.58 92.67 64.03 34.84

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.39 33.85 30.30 18.14 16.35
CRTHF
24GF Score
CARsgen Therapeutics Holdings Ltd CRTHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARsgen Therapeutics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $34.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $34.48 Mil mean?
CARsgen Therapeutics Holdings (CRTHF) has a Research & Development of $34.48 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CARsgen Therapeutics Holdings and its competitors.
Is CARsgen Therapeutics Holdings' Research & Development too high?
CARsgen Therapeutics Holdings' current Research & Development is $34.48 Mil. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Research & Development compare to VRTX and REGN?
CARsgen Therapeutics Holdings' Research & Development of $34.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current Research & Development is $34.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current Research & Development of $34.48 Mil. The current Research & Development is $34.48 Mil. CARsgen Therapeutics Holdings' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current Research & Development is $34.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges 02171:Hong Kong
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
24GF Score

Get the complete analysis for CRTHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.09
Price